Drug intelligence / Profile preview

coagulation factor ix

Development stage
Approved
Lead developer
Pfizer
Modality
Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

Coagulation factor IX is a protein essential for normal blood clotting and hemostasis. It is produced in the liver and circulates in the bloodstream in an inactive form until activated by injury. Upon activation (to Factor IXa), it interacts with Factor VIIIa to form a complex that activates Factor X—an integral step in the blood coagulation cascade[3][5][6][8]. Pharmaceutical forms of this drug include both plasma-derived and recombinant products; recombinant versions are produced using genetically engineered cell lines (such as CHO cells) to replicate human Factor IX[3]. Coagulation factor IX is primarily indicated for the treatment and prevention of bleeding episodes in patients with hemophilia B (congenital Factor IX deficiency or Christmas disease)[1][2][4]. It does not treat hemophilia A or other clotting disorders.

Brand names
BenefixIxinityRixubisIdelvionAlphaNine SDAlprolix
Other names
factor ixrecombinant coagulation factor ixhuman coagulation factor ix
02

Targets

PS (Phosphatidylserine)F10 (Factor Xa)F8 (Coagulation Factor VIIIa)

Beyond the preview

Go deeper on coagulation factor ix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on coagulation factor ix.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call